Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,440Revenue $M201Net Margin (%)-26.9Z-Score-2.4
Enterprise Value $M1,331EPS $-0.4Operating Margin %-8.2F-Score5
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-27.1Higher ROA y-yY
Price/Book39.210-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsN
Price/Sales7.15-y EBITDA Growth Rate %-28.7Current Ratio4.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-11.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M131ROI % (ttm)-196.7Gross Margin Increase y-yY

Gurus Latest Trades with NKTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NKTRJean-Marie Eveillard 2011-12-31 Sold Out -0.003%$4.22 - $5.62
($4.9)
$ 11.3657%Sold Out0
NKTRJean-Marie Eveillard 2011-09-30 Buy $4.98 - $7.65
($5.97)
$ 11.3647%New holding125,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NKTR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NKTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KUEBLER CHRISTOPHER ADirector 2015-01-13Sell15,000$16-26.44 view
CHESS ROBERTDirector 2014-12-29Sell29,500$15.34-23.27 view
Thomsen Jillian B.SVP & Chief Accounting Officer 2014-12-22Sell5,000$15.56-24.36 view
ROBIN HOWARD WPresident & CEO 2014-12-01Sell350,000$17.01-30.81 view
Labrucherie Gil MSVP & General Counsel 2014-12-01Sell120,000$17.02-30.85 view
ROBIN HOWARD WPresident & CEO 2014-11-25Sell600,000$15.25-22.82 view
Lingnau LutzDirector 2014-11-24Sell15,000$15.02-21.64 view
Labrucherie Gil MSVP & General Counsel 2014-11-24Sell10,500$15.04-21.74 view
Labrucherie Gil MSVP & General Counsel 2014-11-03Sell9,900$13.78-14.59 view
KUEBLER CHRISTOPHER ADirector 2013-08-05Sell12,500$12.41-5.16 view

Press Releases about NKTR :

    Quarterly/Annual Reports about NKTR:

    News about NKTR:

    Articles On GuruFocus.com
    Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
    Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
    Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 08 2011 
    MannKind: Deja Vu for the FDA and Afrezza Dec 30 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
    cooldecency99 note on NKTR May 01 2010 
    Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
    Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 


    More From Other Websites
    Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
    Nektar Therapeutics to Present at the 14th Annual Needham Healthcare Conference Apr 13 2015
    Nektar Gets Movantik Milestone Payment from AstraZeneca - Analyst Blog Apr 06 2015
    Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca Apr 02 2015
    Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca Apr 02 2015
    MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients... Mar 31 2015
    MOVANTIK™ (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients... Mar 31 2015
    AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog Mar 20 2015
    AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK In The US Mar 19 2015
    Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Nektar Therapeutics Mar 18 2015
    Nektar Therapeutics (NKTR) Stock Tanks Today on Failed Phase III Breast Cancer Treatment Results Mar 18 2015
    Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog Mar 18 2015
    Nektar's Breast Cancer Candidate Fails in BEACON Study - Analyst Blog Mar 18 2015
    What We’re Trading Mar 18 2015
    Breast cancer drug, key to Nektar growth plans, fails clinical trial Mar 17 2015
    NEKTAR THERAPEUTICS Files SEC form 8-K, Regulation FD Disclosure Mar 17 2015
    Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control... Mar 17 2015
    Nektar drug fails late-stage study in breast cancer patients Mar 17 2015
    Nektar Therapeutics Conference Call to Discuss the results from Phase 3 BEACON study evaluating... Mar 17 2015
    Etirinotecan Pegol (NKTR-102) Prolonged Median Overall Survival by 2.1 Months versus Active Control... Mar 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK